- Kowa
Pitavastatin Demonstrates Sustained Efficacy, Tolerability and LDL-C Target Attainment Over 52 Weeks
Wokingham, England, April 28, 2010 (ots/PRNewswire) - New long-term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who...
- 28.04.2010, 14:01:09
- /
- OTE0014
- Kowa
Pitavastatin is Non-Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 Weeks
Barcelona, Spain (ots/PRNewswire) -
- 01.09.2009, 14:14:08
- /
- OTE0004
Alle Aussendungen
Alle Anhänge
